Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa

摘要: Hidradenitis suppurativa (HS) is a chronic suppurative disease impairing patients’ quality of life (QOL). The standard treatment remains extensive surgery; medical often disappointing. Objectives: Prolonged infliximab efficacy and tolerance in moderate-to-severe forms HS were evaluated. Patients methods: This prospective, monocentric, open, interventional study concerned patients with progressive, ineligible for surgery, or who relapsed after surgery. Infliximab (5 mg/kg) was infused at weeks 0, 2 6, then every 4 weeks. When the response satisfactory, infusion spacing attempted. Results: Ten included, 8 treated 1 year, mean 5 affected sites 18 years evolution. initial DLQI 20/30 (range 9-30). At number involved ( P<0.001) flares P<0.05) had decreased significantly under infliximab, as did severity. QOL improved clearly rapidly all patients, 6/30 P<0.001). Tolerance satisfactory only minor infections, keratoacanthoma one resolving hepatitis. Conclusion: evaluation prolonged use surgical failure showed good without therapeutic escape during first year treatment.